Cost of innovation in the pharmaceutical industry

Amemiya, 1981, Qualitative response models: A survey, Journal of Economic Literature, 19, 1483

Baily, 1972, Research and development costs and returns: The U.S. pharmaceutical industry, Journal of Political Economy, 80, 70, 10.1086/259862

Clymer, 1970, The changing costs and risks of pharmaceutical innovation, 109

Cox, 1984

Feldstein, 1988, Halving the pain of budget balance, Wall Street Journal, 24

1989, F-D-C Reports: The Pink Sheet, 51, 14

Grabowski, 1989, An analysis of U.S. international competitiveness in pharmaceuticals, Managerial and Decision Economics, 27

Grabowski, 1990, Innovation and international competitiveness in pharmaceuticals, 167

Grabowski, 1982, A sensitivity analysis of expected profitability of pharmaceutical research and development, Managerial and Decision Economics, 3, 36, 10.1002/mde.4090030108

Grabowski, 1990, A new look at the returns and risks to pharmaceutical R&D, Management Science, 36, 804, 10.1287/mnsc.36.7.804

Grabowski, 1978, Estimating the effects of regulation on innovation: An international comparative analysis of the pharmaceutical industry, Journal of Law and Economics, 21, 133, 10.1086/466914

Hansen, 1979, The pharmaceutical development process: Estimates of current development costs and times and the effects of regulatory changes, 151

Hansen, 1980, Pharmaceutical development costs by therapeutic categories, University of Rochester Graduate School of Management Working Paper No. GPB-80-6

Joglekar, 1986, A closer look at the returns and risks of pharmaceutical R&D, Journal of Health Economics, 5, 153, 10.1016/0167-6296(86)90003-2

Mansfield, 1987, Price indexes for R&D inputs, 1969–1983, Management Science, 33, 124, 10.1287/mnsc.33.1.124

Mattison, 1988, New drug development in the United States, 1963–1984, Clinical Pharmacology and Therapeutics, 43, 15, 10.1038/clpt.1988.35

McFadden, 1974, Conditional logit analysis of qualitative choice behavior, 105

Mund, 1970, The return on investment of the innovative pharmaceutical firm, 125

National Academy of Engineering, 1983

Pharmaceutical Manufacturers Association, 1987

Pharmaceutical Manufactures Association, 1968

Sarett, 1974, FDA regulations and their influence on future research and development, Research Management, 18, 10.1080/00345334.1974.11756229

Schnee, 1972, Development costs: Determinants and overruns, Journal of Business, 347, 10.1086/295463

Sheck, 1984, Success rates in the United States drug development system, Clinical Pharmacology and Therapeutics, 36, 574, 10.1038/clpt.1984.224

Statman, 1983

Thomas, 1990, Spare the rod and spoil the industry: Vigorous competition and vigorous regulation promote global competitive advantage, International Joseph Schumpeter Society Meetings

Tucker, 1988, The outcome of research on new molecular entities commencing clinical research in the years 1976–1978, 77

U.S. Bureau of Economic Analysis, Government Division, 1986

U.S. Congress, House, Subcommittee on Health and the Environment of the Committee on Energy and Commerce, 1985, Prescription drug price increases

U.S. Congress, House, Subcommittee on Health and the Environment of the Committee on Energy and Commerce, 1987, Medical devices and drug issues

U.S. Congress, Senate, Special Committee on Aging, 1989, Prescription drug prices: Are we getting our money's worth?

U.S. Department of Health and Human Services, 1990, Justification of appropriation estimates for committee on appropriations, Vol. 10

Wiggins, 1981, The pharmaceutical research and development decision process

Wiggins, 1987

Woltman, 1989, Reviewing the bidding: R&D costs and profitability of new chemical entities, Journal of Research in Pharmaceutical Economics, 1, 49